{"ATC Code":"N - Nervous system","Abbreviation":"","Aliases":["Methaminodiazepoxide","Librium","Chlozepid","Librelease","Libritabs","Elenium","Chlorodiazepoxide","Clopoxide","Helogaphen","Silibrin"],"Biological Half-Life":"24-48 hours","CAS":"58-25-3","CanonicalSMILES":"CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O","ChEBI":"CHEBI:3611","ChEMBL":"CHEMBL451","ChemicalClasses":["benzodiazepine"],"Color/Form":"Yellow crystalline powder","Decomposition":"When heated to decomposition it emits very toxic fumes of nitroxides.","Dosing Info":[],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"Chlordiazepoxide is indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.   In combination with amitriptyline, chlordiazepoxide is indicated for the treatment of moderate to severe depression. In combination with clidinium, chlordiazepoxide is indicated to control emotional and somatic factors in gastrointestinal disorders, and is used as adjunctive therapy in the treatment of peptic ulcer, irritable bowel syndrome and acute enterocolitis.","Drug Warnings":"CHLORDIAZEPOXIDE HYDROCHLORIDE REQUIRES ... PRECAUTIONS REGARDING ITS USE IN PT WITH KNOWN HYPERSENSITIVITY, ELDERLY \u0026 EXCESSIVELY DEPRESSED INDIVIDUALS, PREGNANT \u0026 LACTATING MOTHERS, PT WITH KNOWN RENAL \u0026 HEPATIC IMPAIRMENT, PT ON OTHER CNS DEPRESSANT DRUGS, \u0026 IN PT WITH EITHER A HISTORY OF DRUG ADDICTION OR INDISCRIMINANT ALTERATION OF DRUG DOSAGE. /CHLORDIAZEPOXIDE HYDROCHLORIDE/","DrugClasses":["depressant"],"European Community (EC) Number":"200-371-0","FDA Pharmacological Classification":"6RZ6XEZ3CR","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine","InChI":"InChI=1S/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9,21H,10H2,1H3","InChIKey":"BUCORZSTKDOEKQ-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)","Melting Point":"236-236.5","MolecularFormula":"C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e14\u003c/sub\u003eClN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"299.75 g/mol","Odor":"PRACTICALLY ODORLESS","Pharmacodynamics":"Chlordiazepoxide has antianxiety, sedative, appetite-stimulating and weak analgesic actions. The drug seems to block EEG arousal from stimulation in the brain stem reticular formation. The drug has been studied extensively in many species of animals and these studies are suggestive of action on the limbic system of the brain, which recent evidence indicates is involved in emotional responses. Hostile monkeys were made tame by oral drug doses which did not cause sedation. Chlordiazepoxide revealed a \"taming\" action with the elimination of fear and aggression. The taming effect of chlordiazepoxide was further demonstrated in rats made vicious by lesions in the septal area of the brain. The drug dosage which effectively blocked the vicious reaction was well below the dose which caused sedation in these animals.","PubChemId":2712,"Record Description":["Chlordiazepoxide can cause developmental toxicity according to state or federal government labeling requirements.","7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine is a benzodiazepine.","Chlordiazepoxide is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.","Chlordiazepoxide is a Benzodiazepine.","Chlordiazepoxide is an orally available benzodiazepine used for therapy of anxiety disorders and alcohol withdrawal syndromes. As with other benzodiazepines, chlordiazepoxide is not associated with serum aminotransferase or alkaline phosphatase elevations during therapy, and clinically apparent liver injury from chlordiazepoxide has been reported but is rare.","Chlordiazepoxide is a long-acting benzodiazepine with anxiolytic, sedative and hypnotic activity. Chlordiazepoxide exerts its effect by binding to the benzodiazepine site at the gamma-aminobutyric acid (GABA) receptor-chloride ionophore complex in the central nervous system (CNS). This leads to an increase in the opening of chloride channels, membrane hyperpolarization and increases the inhibitory effect of GABA on the CNS.","CHLORDIAZEPOXIDE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1960 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA.","Chlordiazepoxide is only found in individuals that have used or taken this drug. It is an anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor.BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties.","An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.","See also: Chlordiazepoxide Hydrochloride (active moiety of); Chlordiazepoxide; estrogens, esterified (component of); Amitriptyline Hydrochloride; Chlordiazepoxide (component of) ... View More ...","Chlordiazepoxide can cause developmental toxicity according to state or federal government labeling requirements.","7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine is a benzodiazepine."],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Chlordiazepoxide"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q106042110"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB00475"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/2712"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.10248513.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL451"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3611"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=58-25-3"},{"name":"KEGG","url":"https://www.kegg.jp/entry/D00267"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/6RZ6XEZ3CR"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID40861935"}],"Reported Fatal Dose":"A few deaths have been reported at doses greater than 700 mg of ... chlordiazepoxide.","Solubility":"FREELY SOL IN WATER; SPARINGLY SOL IN ETHANOL; INSOL IN CHLOROFORM, DIETHYL ETHER \u0026 PETROLEUM ETHER /CHLORDIAZEPOXIDE HYDROCHLORIDE/","Stability/Shelf Life":"HYDROLYZES IN ACID @ 100 °C /CHLORDIAZEPOXIDE HYDROCHLORIDE/","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="91.422mm" version="1.2" viewBox="0 0 96.849 91.422" width="96.849mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="92.0" stroke="none" width="97.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <path class="bond" d="M96.289 5.315c.082 -.538 -.374 -1.159 -.912 -1.241c-.538 -.082 -1.158 .374 -1.24 .912c-.083 .538 -.703 .993 -1.241 .911c-.538 -.082 -.994 -.703 -.912 -1.241c.083 -.538 -.373 -1.158 -.911 -1.24c-.538 -.083 -1.158 .373 -1.241 .911c-.082 .538 -.702 .994 -1.24 .911c-.538 -.082 -.994 -.702 -.912 -1.24c.083 -.538 -.373 -1.159 -.911 -1.241c-.538 -.082 -1.159 .373 -1.241 .911" fill="none" id="mol1bnd1" stroke="#000000" stroke-width=".7"/>
                  
            <g class="bond" id="mol1bnd2">
                        
                <line x1="78.408" x2="71.695" y1="6.525" y2="14.904"/>
                        
                <line x1="80.311" x2="74.559" y1="8.049" y2="15.229"/>
                      
                <line class="hi" stroke="#3050F8" x1="78.408" x2="75.0515" y1="6.525" y2="10.714500000000001"/>
                <line class="hi" stroke="#3050F8" x1="80.311" x2="77.435" y1="8.049" y2="11.639"/>
            </g>
                  
            <line class="bond" id="mol1bnd3" x1="71.695" x2="78.299" y1="14.904" y2="28.62"/>
                  
            <line class="bond" id="mol1bnd4" x1="78.299" x2="73.482" y1="28.62" y2="38.624"/>
                  
            <line class="bond" id="mol1bnd5" x1="68.391" x2="56.862" y1="43.105" y2="45.79"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="44.975" x2="56.862" y1="36.24" y2="45.79"/>
                        
                <line x1="47.413" x2="57.464" y1="35.071" y2="43.146"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="44.975" x2="31.767" y1="36.24" y2="43.86"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="18.559" x2="31.767" y1="36.24" y2="43.86"/>
                        
                <line x1="20.997" x2="31.767" y1="34.831" y2="41.044"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="18.559" x2="18.559" y1="36.24" y2="21.0"/>
                  
            <g class="bond" id="mol1bnd10">
                        
                <line x1="31.767" x2="18.559" y1="13.38" y2="21.0"/>
                        
                <line x1="31.767" x2="20.997" y1="16.195" y2="22.408"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd11" x1="31.767" x2="44.975" y1="13.38" y2="21.0"/>
                  
            <line class="bond" id="mol1bnd12" x1="44.975" x2="44.975" y1="36.24" y2="21.0"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="53.83" x2="44.975" y1="13.885" y2="21.0"/>
                        
                <line x1="55.357" x2="47.413" y1="15.786" y2="22.168"/>
                      
                <line class="hi" stroke="#3050F8" x1="53.83" x2="49.4025" y1="13.885" y2="17.4425"/>
                <line class="hi" stroke="#3050F8" x1="55.357" x2="51.385" y1="15.786" y2="18.977"/>
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="71.695" x2="60.166" y1="14.904" y2="12.219"/>
                  
            <line class="bond" id="mol1bnd15" x1="18.559" x2="6.875" y1="36.24" y2="42.988"/>
                  
            <line class="bond" id="mol1bnd16" x1="56.862" x2="53.476" y1="45.79" y2="60.649"/>
                  
            <g class="bond" id="mol1bnd17">
                        
                <line x1="64.662" x2="53.476" y1="71.013" y2="60.649"/>
                        
                <line x1="61.971" x2="52.851" y1="71.844" y2="63.394"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd18" x1="64.662" x2="61.276" y1="71.013" y2="85.872"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="46.705" x2="61.276" y1="90.368" y2="85.872"/>
                        
                <line x1="47.331" x2="59.211" y1="87.623" y2="83.957"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="46.705" x2="35.52" y1="90.368" y2="80.004"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="38.906" x2="35.52" y1="65.145" y2="80.004"/>
                        
                <line x1="40.97" x2="38.21" y1="67.06" y2="79.172"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="53.476" x2="38.906" y1="60.649" y2="65.145"/>
                  
            <line class="bond" id="mol1bnd23" x1="74.512" x2="78.751" y1="45.851" y2="51.142"/>
                  
            <path class="atom" d="M83.165 5.459h-.721l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M73.636 44.785h-.72l-2.62 -4.066h-.029q.012 .238 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.607 4.054h.03q-.006 -.107 -.018 -.328q-.012 -.22 -.023 -.476q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm5" stroke="none"/>
                  
            <path class="atom" d="M58.802 13.899h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm13" stroke="none"/>
                  
            <path class="atom" d="M2.906 42.046q-.786 -.0 -1.239 .53q-.452 .524 -.452 1.446q-.0 .911 .417 1.447q.422 .53 1.268 .53q.321 -.0 .607 -.054q.291 -.059 .565 -.143v.536q-.274 .101 -.565 .149q-.292 .054 -.697 .054q-.744 -.0 -1.25 -.31q-.5 -.31 -.75 -.875q-.25 -.572 -.25 -1.34q.0 -.744 .268 -1.309q.274 -.566 .804 -.881q.529 -.322 1.279 -.322q.78 .0 1.352 .286l-.244 .524q-.226 -.101 -.506 -.185q-.274 -.083 -.607 -.083zM5.662 46.469h-.601v-5.215h.601v5.215z" fill="#1FF01F" id="mol1atm14" stroke="none"/>
                  
            <g class="atom" id="mol1atm21">
                        
                <path d="M83.483 54.226q.0 .756 -.256 1.328q-.256 .565 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.309q.25 -.566 .756 -.881q.506 -.316 1.274 -.316q.732 .0 1.232 .316q.5 .309 .756 .875q.256 .565 .256 1.327zM79.62 54.226q-.0 .923 .387 1.459q.392 .53 1.22 .53q.839 -.0 1.22 -.53q.387 -.536 .387 -1.459q.0 -.928 -.387 -1.452q-.381 -.524 -1.208 -.524q-.834 -.0 -1.226 .524q-.393 .524 -.393 1.452z" fill="#FF0D0D" stroke="none"/>
                        
                <path d="M87.789 56.679h-.619v-2.286h-2.512v2.286h-.613v-4.899h.613v2.071h2.512v-2.071h.619v4.899z" fill="#FF0D0D" stroke="none"/>
                      
            </g>
                
            <line class="hi" id="mol1bnd4" stroke="#3050F8" x1="73.482" x2="75.8905" y1="38.624" y2="33.622"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="68.391" x2="62.62650000000001" y1="43.105" y2="44.4475"/>
            <line class="hi" id="mol1bnd14" stroke="#3050F8" x1="60.166" x2="65.9305" y1="12.219" y2="13.561499999999999"/>
            <line class="hi" id="mol1bnd15" stroke="#1FF01F" x1="6.875" x2="12.717" y1="42.988" y2="39.614000000000004"/>
            <line class="hi" id="mol1bnd23" stroke="#3050F8" x1="74.512" x2="76.6315" y1="45.851" y2="48.4965"/>
            <line class="hi" id="mol1bnd23" stroke="#FF0D0D" x1="78.751" x2="76.6315" y1="51.142" y2="48.4965"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Adjuvants, Anesthesia; Anti-Anxiety Agents, Benzodiazepine; GABA Modulators; Sedatives, Nonbarbiturate","Title":"Chlordiazepoxide","UNII":"6RZ6XEZ3CR","Wikidata":"Q106042110","XLogP":2.4}